Tennessee Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center

• Category: Corporations - Public - Licenses
• State: Multi-State
• Control #: US-EG-9161
• Format: Word; Rich Text

Description

Collateral License Agreement between GeneLink, Inc. and The University of North Texas Health Science Center at Forth Worth dated July 1, 1996. 2 pages Tennessee Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center: A Tennessee Collateral License Agreement is a legal contract between Gentling, Inc. (the licensee) and The University of North Texas Health Science Center (the licensor) that outlines the terms and conditions for the licensing of intellectual property rights. This agreement enables Gentling, Inc. to utilize the technology or innovation developed by The University of North Texas Health Science Center for commercial purposes, typically in the field of biotechnology or healthcare. The Tennessee Collateral License Agreement permits Gentling, Inc. to access and exploit the licensed intellectual property, which can include patents, copyrights, trademarks, or trade secrets. This agreement establishes the rights and responsibilities of both parties, ensuring that the licensor's underlying intellectual property is protected, and the licensee has the necessary authorization to develop, manufacture, market, and sell products or services based on the licensed technology. Key components of the Tennessee Collateral License Agreement include: 1. License Scope: This section describes the specific technology or innovation being licensed, including any limitations or exclusions. 2. License Fees: The agreement determines the financial obligations of Gentling, Inc. In terms of licensing fees, royalties, or revenue sharing arrangements, ensuring fair compensation for the use of the licensor's intellectual property. 3. Intellectual Property Ownership: The agreement clarifies the ownership of the licensed intellectual property, typically confirming that The University of North Texas Health Science Center retains ownership rights while granting specific usage rights to Gentling, Inc. 4. Compliance and Reporting: Gentling, Inc. is obligated to adhere to certain obligations, such as maintaining specific quality standards, providing progress reports, and complying with applicable laws and regulations. 5. Term and Termination: The agreement stipulates the duration of the license, including any renewal clauses, as well as the conditions under which either party can terminate the agreement. 6. Dispute Resolution: In the event of disagreements or disputes, the agreement outlines the procedures for resolving conflicts, typically through negotiation, mediation, or arbitration. 7. Confidentiality: Both parties agree to maintain the confidentiality of any proprietary or sensitive information shared during the agreement's term. Different types of Tennessee Collateral License Agreements between Gentling, Inc. and The University of North Texas Health Science Center may include variations in terms and conditions based on the specific technology or innovation being licensed. For example, there may be different agreements for licensing genetic sequencing technology, drug discovery platforms, or diagnostic methods. The terms and obligations within the Tennessee Collateral License Agreement will be tailored accordingly to the specific intellectual property involved.

Tennessee Collateral License Agreement between Gentling, Inc. and The University of North Texas Health Science Center: A Tennessee Collateral License Agreement is a legal contract between Gentling, Inc. (the licensee) and The University of North Texas Health Science Center (the licensor) that outlines the terms and conditions for the licensing of intellectual property rights. This agreement enables Gentling, Inc. to utilize the technology or innovation developed by The University of North Texas Health Science Center for commercial purposes, typically in the field of biotechnology or healthcare. The Tennessee Collateral License Agreement permits Gentling, Inc. to access and exploit the licensed intellectual property, which can include patents, copyrights, trademarks, or trade secrets. This agreement establishes the rights and responsibilities of both parties, ensuring that the licensor's underlying intellectual property is protected, and the licensee has the necessary authorization to develop, manufacture, market, and sell products or services based on the licensed technology. Key components of the Tennessee Collateral License Agreement include: 1. License Scope: This section describes the specific technology or innovation being licensed, including any limitations or exclusions. 2. License Fees: The agreement determines the financial obligations of Gentling, Inc. In terms of licensing fees, royalties, or revenue sharing arrangements, ensuring fair compensation for the use of the licensor's intellectual property. 3. Intellectual Property Ownership: The agreement clarifies the ownership of the licensed intellectual property, typically confirming that The University of North Texas Health Science Center retains ownership rights while granting specific usage rights to Gentling, Inc. 4. Compliance and Reporting: Gentling, Inc. is obligated to adhere to certain obligations, such as maintaining specific quality standards, providing progress reports, and complying with applicable laws and regulations. 5. Term and Termination: The agreement stipulates the duration of the license, including any renewal clauses, as well as the conditions under which either party can terminate the agreement. 6. Dispute Resolution: In the event of disagreements or disputes, the agreement outlines the procedures for resolving conflicts, typically through negotiation, mediation, or arbitration. 7. Confidentiality: Both parties agree to maintain the confidentiality of any proprietary or sensitive information shared during the agreement's term. Different types of Tennessee Collateral License Agreements between Gentling, Inc. and The University of North Texas Health Science Center may include variations in terms and conditions based on the specific technology or innovation being licensed. For example, there may be different agreements for licensing genetic sequencing technology, drug discovery platforms, or diagnostic methods. The terms and obligations within the Tennessee Collateral License Agreement will be tailored accordingly to the specific intellectual property involved.